Elsevier

Neuropharmacology

Volume 136, Part B, 1 July 2018, Pages 202-215
Neuropharmacology

Invited review
Evidence for altered insulin receptor signaling in Alzheimer's disease

https://doi.org/10.1016/j.neuropharm.2018.01.008Get rights and content

Highlights

  • Metabolic disease increases the risk of developing cognitive decline and dementia.

  • AD is associated with peripheral metabolic alterations.

  • Insulin/insulin sensitivity is altered in the AD brain.

  • Insulin and Insulin sensitizers can improve cognitive function in AD.

Abstract

Epidemiological data have shown that metabolic disease can increase the propensity for developing cognitive decline and dementia, particularly Alzheimer's disease (AD). While this interaction is not completely understood, clinical studies suggest that both hyper- and hypoinsulinemia are associated with an increased risk for developing AD. Indeed, insulin signaling is altered in post-mortem brain tissue from AD patients and treatments known to enhance insulin signaling can improve cognitive function. Further, clinical evidence has shown that AD patients and mouse models of AD often display alterations in peripheral metabolism. Since insulin is primarily derived from the periphery, it is likely that changes in peripheral insulin levels lead to alterations in central nervous system (CNS) insulin signaling and could contribute to cognitive decline and pathogenesis. Developing a better understanding of the relationship between alterations in peripheral metabolism and cognitive function might provide a foundation for the development of better treatment options for patients with AD. In this article we will begin to piece together the present data defining this relationship by briefly discussing insulin signaling in the periphery and CNS, its role in cognitive function, insulin's relationship to AD, peripheral metabolic alterations in mouse models of AD and how information from these models helps understand the mechanisms through which these changes potentially lead to impairments in insulin signaling in the CNS, and potential ways to target insulin signaling that could improve cognitive function in AD.

This article is part of the Special Issue entitled ‘Metabolic Impairment as Risk Factors for Neurodegenerative Disorders.’

Introduction

Metabolic diseases (e.g., obesity, metabolic syndrome, type 2 diabetes) are known to increase the propensity for developing cognitive decline and dementia (Arvanitakis et al., 2004, Biessels and Reagan, 2015, Leibson et al., 1997, Ott et al., 1999, Yaffe et al., 2004, Yoshitake et al., 1995). Moreover, insulin signaling is altered in post-mortem brain tissue from patients with Alzheimer's disease (AD) (Bomfim et al., 2012, Jolivalt et al., 2010, Liu et al., 2011, Moloney et al., 2010, Steen et al., 2005), and intranasal treatment with insulin has been shown to improve cognitive function in patients with aging-related mild cognitive impairment and mild-to-moderate AD (Benedict et al., 2007, Benedict et al., 2004, Craft et al., 2012, Krug et al., 2010). Thus, alterations in insulin signaling are likely to contribute to both peripheral metabolic changes and the cognitive decline that can accompany metabolic dysfunction. Indeed, several studies demonstrate that insulin and many of its downstream targets can affect neuronal activity in a manner that favors synaptic plasticity and improves cognitive performance in non-pathological conditions (Das et al., 2005, Grillo et al., 2015, Zhao et al., 1999).

These observations lead to several relevant and important questions. For instance, is there a correlation between the time course of altered peripheral metabolic phenotype, impaired CNS insulin signaling, and cognitive decline? If insulin signaling is impaired prior to cognitive decline, it may play a potential role in pathogenesis and cognitive dysfunction; on the other hand, if the two phenomena occur concomitantly, altered insulin signaling could simply be a consequence of disease progression. What underlies the change in CNS insulin signaling? Factors that could contribute to impaired CNS insulin signaling include a decrease in brain insulin levels (e.g., due to decreased peripheral production or altered capacity for insulin to cross the blood brain barrier) or a change in CNS insulin receptor (IR) sensitivity (e.g., IR desensitization due to elevated insulin levels). Could impaired peripheral insulin signaling or responsivenes be a reliable biomarker for detecting individuals susceptible to cognitive decline and dementia? Further, can pharmacological or experimental manipulations known to improve peripheral insulin signaling (e.g. insulin sensitizers or exercise) improve cognitive function in subjects with cognitive decline/dementia? Taken together, these questions are extremely significant given epidemiological data reporting an alarming increase in the incidence and prevalence of metabolic disorders worldwide (O'Neill and O'Driscoll, 2015).

While the scientific community is far from understanding the complex interaction between metabolic alterations, altered insulin signaling and cognitive decline, on-going animal model and clinical/epidemiological studies are beginning to provide insights into this relationship. In this article we briefly review the basic mechanisms of insulin signaling in the periphery and CNS and then discuss data demonstrating: 1) a role for insulin in cognitive function; 2) a relationship between insulin and human AD; 3) peripheral metabolic alterations in mouse models of AD and how these changes could potentially lead to impaired CNS insulin signaling; and 4) potential ways to target insulin signaling that could improve cognitive function in AD. Understanding how and when peripheral metabolic alterations and impaired CNS insulin signaling occur during AD pathogenesis could improve the identification of individuals who are susceptible for developing AD, and could thus allow for earlier and possibly more effective intervention. Further, understanding this complex relationship could also help in the development of novel metabolic-based therapies or pharmacological therapeutics for AD and other cognitive disorders.

Section snippets

Insulin signaling

Insulin plays a variety of roles in the periphery, most notably in the regulation of tissue metabolism by controlling cellular glucose uptake. In contrast, the brain was previously considered insulin insensitive. However, it is now known that insulin does play several roles within the CNS at the cellular or network levels, including the regulation of neuronal survival, feeding behavior, and cognition (Kleinridders et al., 2014). IRs are differentially expressed throughout the CNS, with greatest

The role of insulin in cognitive function

Ample data suggest that insulin can play a role in normal cognitive function, although exactly how it does so is still poorly understood. First, IRs are found in the CNS in regions involved with learning and memory, including the hippocampus and cerebral cortex (Biessels and Reagan, 2015). Second, exogenous treatment with insulin can improve memory in humans and animals. Peripheral administration of insulin under euglycemic conditions increases cognitive function as assessed by verbal memory

Alzheimer's disease and altered insulin signaling

AD is a neurodegenerative condition characterized by profound memory loss, the formation of β-amyloid–containing plaques and neurofibrillary tangles consisting of hyperphosphorylated tau (the classical histological hallmarks of AD) and localized CNS hypometabolism. Despite tremendous advancements in our understanding of AD neuropathology, there are no therapeutic strategies that consistently relieve cognitive symptoms or prevent, cure or slow its progression. AD is currently the 6th leading

Mouse models of AD and peripheral insulin resistance

Before proceeding, important caveats regarding AD animal model studies need to be noted. First, rodents do not develop AD. To create animal models to study AD, scientists have introduced mutated genes associated with AD pathology into the murine genome (e.g. APP, presensilin-1 and tau). This transgenic approach has led to a plethora of available models (over 150 are listed on the Jackson Laboratory web site: www.jax.org). Noteworthy among these are the Tg2576 model (APPswe, APP Swedish

Altered CNS insulin signaling

Altered peripheral glucose regulation and insulin levels/sensitivity could affect AD pathogenesis and cognitive decline through a variety of mechanisms. In general, CNS insulin is believed to be primarily derived from the periphery and relies on an active transport mechanism to cross the BBB (Banks, 2004). This transporter appears to be saturated during euglycemic conditions, but can be affected by a variety of factors including diet, plasma glucose levels, diabetes, and obesity (Banks, 2004).

Improving insulin sensitivity decreases AD-like pathology

Thus far we have presented data demonstrating that impaired peripheral metabolism is correlated with compromised CNS insulin signaling, and have argued that this can contribute to cognitive decline and pathogenesis in AD. If impaired insulin levels/sensitivity can contribute to AD, can the converse be true? Specifically, can improving CNS insulin signaling ameliorate AD-related pathology and cognitive decline? Several studies suggest an affirmative answer. Specifically, studies have shown that:

Conclusion

In conclusion, epidemiological data reveal that metabolic disease is associated with an increased risk of developing dementia, in particular AD. Further, clinical studies suggest that either hyper- or hypoinsulinemia is associated with an increased risk for developing AD and that treatments known to improve/enhance insulin signaling can improve cognitive function in both normal subjects and AD patients. The mechanisms linking insulin to cognitive function remain to be completely understood.

References (218)

  • Y. Deng et al.

    Dysregulation of insulin signaling, glucose transporters, O-GlcNAcylation, and phosphorylation of tau and neurofilaments in the brain: implication for Alzheimer's disease

    Am. J. Pathol.

    (2009)
  • J.D. English et al.

    Activation of p42 mitogen-activated protein kinase in hippocampal long term potentiation

    J. Biol. Chem.

    (1996)
  • S.T. Ferreira et al.

    Inflammation, defective insulin signaling, and neuronal dysfunction in Alzheimer's disease

    Alzheimer's Dementia

    (2014)
  • D.P. Figlewicz et al.

    Insulin reduces norepinephrine transporter mRNA in vivo in rat locus coeruleus

    Brain Res.

    (1993)
  • S. Gengler et al.

    Val(8)GLP-1 rescues synaptic plasticity and reduces dense core plaques in APP/PS1 mice

    Neurobiol. Aging

    (2012)
  • P. Grammas et al.

    Inflammatory factors are elevated in brain microvessels in Alzheimer's disease

    Neurobiol. Aging

    (2001)
  • C. a Grillo et al.

    Insulin-stimulated translocation of GLUT4 to the plasma membrane in rat hippocampus is PI3-kinase dependent

    Brain Res.

    (2009)
  • A. Gupta et al.

    Peripheral insulin-sensitizer drug metformin ameliorates neuronal insulin resistance and Alzheimer’s-like changes

    Neuropharmacology

    (2011)
  • V.K.M. Halagappa et al.

    Intermittent fasting and caloric restriction ameliorate age-related behavioral deficits in the triple-transgenic mouse model of Alzheimer's disease

    Neurobiol. Dis.

    (2007)
  • L. Han et al.

    Exendin-4 directly improves endothelial dysfunction in isolated aortas from obese rats through the cAMP or AMPK–eNOS pathways

    Diabetes Res. Clin. Pract.

    (2012)
  • E. Hayashi-Park et al.

    Experimentally induced diabetes worsens neuropathology, but not learning and memory, in middle aged 3xTg mice

    Behav. Brain Res.

    (2017)
  • M. Hong et al.

    Lithium reduces tau phosphorylation by inhibition of glycogen synthase kinase-3

    J. Biol. Chem.

    (1997)
  • K. Hsiao

    Transgenic mice expressing Alzheimer amyloid precursor proteins

    Exp. Gerontol.

    (1998)
  • C.-C. Huang et al.

    Rap1-induced p38 mitogen-activated protein kinase activation facilitates AMPA receptor trafficking via the GDI·Rab5 complex

    J. Biol. Chem.

    (2004)
  • J.L. Jankowsky et al.

    Co-expression of multiple transgenes in mouse CNS: a comparison of strategies

    Biomol. Eng.

    (2001)
  • C.G. Jolivalt et al.

    Type 1 diabetes exaggerates features of Alzheimer's disease in APP transgenic mice

    Exp. Neurol.

    (2010)
  • C. Julien et al.

    High-fat diet aggravates amyloid-beta and tau pathologies in the 3xTg-AD mouse model

    Neurobiol. Aging

    (2010)
  • H. Kanety et al.

    Tumor necrosis factor alpha-induced phosphorylation of insulin receptor substrate-1 (IRS-1). Possible mechanism for suppression of insulin-stimulated tyrosine phosphorylation of IRS-1

    J. Biol. Chem.

    (1995)
  • M.-A. Abbott et al.

    The insulin receptor tyrosine kinase substrate p58/53 and the insulin receptor are components of CNS synapses

    J. Neurosci.

    (1999)
  • P.A. Adlard et al.

    Voluntary exercise decreases amyloid load in a transgenic model of Alzheimer's disease

    J. Neurosci.

    (2005)
  • A. Aguzzi et al.

    Microglia: scapegoat, saboteur, or something else?

    Science

    (2013)
  • G. Ahmadian et al.

    Tyrosine phosphorylation of GluR2 is required for insulin-stimulated AMPA receptor endocytosis and LTD

    EMBO J.

    (2004)
  • Z. Arvanitakis et al.

    Diabetes mellitus and risk of alzheimer disease and decline in cognitive function

    Arch. Neurol.

    (2004)
  • F.M. Ashcroft

    K(ATP) channels and insulin secretion: a key role in health and disease

    Biochem. Soc. Trans.

    (2006)
  • C.J. Bailey et al.

    Glucose tolerance and plasma insulin of the rat in relation to the oestrous cycle and sex hormones

    Horm. Metab. Res.

    (1972)
  • W.A. Bauman et al.

    Increased intake of calcium reverses vitamin B12 malabsorption induced by metformin

    Diabetes Care

    (2000)
  • G.D. Baura et al.

    Saturable transport of insulin from plasma into the central nervous system of dogs in vivo. A mechanism for regulated insulin delivery to the brain

    J. Clin. Invest.

    (1993)
  • E.C. Beattie et al.

    Regulation of AMPA receptor endocytosis by a signaling mechanism shared with LTD

    Nat. Neurosci.

    (2000)
  • C. Benedict et al.

    Intranasal insulin to improve memory function in humans

    Neuroendocrinology

    (2007)
  • G.J. Biessels et al.

    Hippocampal insulin resistance and cognitive dysfunction

    Nat. Rev. Neurosci.

    (2015)
  • E.M. Blalock et al.

    Effects of long-term pioglitazone treatment on peripheral and central markers of aging

    PLoS One

    (2010)
  • A. Bloch-Damti et al.

    Proposed mechanisms for the induction of insulin resistance by oxidative stress

    Antioxidants Redox Signal.

    (2005)
  • G.S. Bloom et al.

    Reduced brain insulin signaling: a seminal process in Alzheimer's disease pathogenesis

    Neuropharmacology

    (2017)
  • T.R. Bomfim et al.

    An anti-diabetes agent protects the mouse brain from defective insulin signaling caused by Alzheimer's disease- associated Aβ oligomers

    J. Clin. Invest.

    (2012)
  • J. Boucher et al.

    Insulin receptor signaling in normal and insulin-resistant states

    Cold Spring Harb. Perspect. Biol.

    (2014)
  • J. Buteau et al.

    Glucagon-like peptide-1 promotes DNA synthesis, activates phosphatidylinositol 3-kinase and increases transcription factor pancreatic and duodenal homeobox gene 1 (PDX-1) DNA binding activity in beta (INS-1)-cells

    Diabetologia

    (1999)
  • Y. Cai et al.

    BACE1 elevation is involved in amyloid plaque development in the triple transgenic model of Alzheimer's disease: differential Aβ antibody labeling of early-onset axon terminal pathology

    Neurotox. Res.

    (2012)
  • J. Cedernaes et al.

    Determinants of shortened, disrupted, and mistimed sleep and associated metabolic health consequences in healthy humans

    Diabetes

    (2015)
  • E.S. Chan et al.

    ApoE4 expression accelerates hippocampus-dependent cognitive deficits by enhancing Aβ impairment of insulin signaling in an Alzheimer's disease mouse model

    Sci. Rep.

    (2016)
  • J.-P. Chaput et al.

    Association of sleep duration with type 2 diabetes and impaired glucose tolerance

    Diabetologia

    (2007)
  • Cited by (0)

    View full text